Human Interleukin 2: Biochemistry, Physiology, and Possible Pathogenetic Role in Immunodeficiency Syndromes

References

• Paetkau V. Lymphokines on the move. Nature (London) 1981; 294: 24–31
   Google Scholar
• Sporn M B, Todaro G J. Autocrine secretion and malignant transformation of cells. New Engl J Med 1980; 303: 878–880
   PubMed Web of Science ®Google Scholar
• Morgan D A, Ruscetti F W, Gallo R C. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (Wash DC) 1976; 193: 1007
   PubMed Web of Science ®Google Scholar
• Henney G S, Kuribayashi K, Kern D E, Gillis S. Interleukin 2 augments natural killer cell activity. Nature (London) 1981; 291: 335–338
   PubMed Web of Science ®Google Scholar
• Hefeneider S H, Conlon P J, Henney C S, Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983; 130: 222–227
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Welte K, Mertelsmann R, O'Reilly R, Dupont B. Interleukin 2 dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies. J Immunol 1983; 130: 2635–2643
   PubMed Web of Science ®Google Scholar
• Domzig W, Stadler B M, Herberman R B. Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol 1983; 130: 1970–1973
   PubMed Web of Science ®Google Scholar
• Merluzzi V J, Welte K, Savage D M, Mertelsmann R. Expansion of cyclophosphamide resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J Immunol 1983; 131: 806–809
   PubMed Web of Science ®Google Scholar
• Grimm E A, Ramsey K M, Mazumder A, Wilson D J, Djeu J Y, Rosenberg S A. Lymphokine activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 1983; 157: 884–897
   PubMed Web of Science ®Google Scholar
• Merluzzi V J, Savage D M, Mertelsmann R, Welte K. Generation of nonspecific murine cytotoxic T cells in vitro by purified human interleukin 2. Cell Immunol 1984; 84: 74–84
   PubMed Web of Science ®Google Scholar
• Ruscetti F W, Gallo R C. Human T lymphocyte growth factor: Regulation of growth and function of T lymphocytes. Blood 1981; 57: 379–394
   PubMed Web of Science ®Google Scholar
• Gillis S, Mochizuki D Y, Conlon P J, Hefeneider S H, Ramthun C A, Gillis A E, Frank M B, Henney C S, Watson J D. Molecular characterization of interleukin 2. Immunol Rev 1982; 63: 167
   PubMed Web of Science ®Google Scholar
• Venuta S, Mertelsmann R, Welte K, Feldman S P, Wang C Y, Moore M AS. Production and regulation of interleukin 2 in human lymphoblastic leukemias studies with T cell monoclonal antibodies. Blood 1983; 61: 781–789
   PubMed Web of Science ®Google Scholar
• Miller G, Feldman S, Welte K, Moore M AS, Mertelsmann R. Interleukin 2 (IL2) requirements of the colony assay for common acute lymphoblastic leukemia (cALL) and chronic lymphocytic leukemia (CLL). Proceedings of the American Association of Cancer Research, TorontoCanada, 1984, 1040, Abstract
   Google Scholar
• Welte K, Wang C Y, Mertelsmann R, Venuta S, Feldman S P, Moore M AS. Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156: 454–464
   PubMed Web of Science ®Google Scholar
• Welte K, Venuta S, Wang C Y, Feldman S P, Ciobanu N, Kruger G, Feickert H J, Merluzzi J, Flomenberg N, Moore M AS, Mertelsmann R. Human interleukin 2: physiology, biochemistry and pathophysiology in lymphoblastic leukemias and immunodeficiency syndromes. Modern Trends in Human Leukemia V, R Neth, R C Gallo, M F Greaves, M AS Moore, K Winkler. Springer-Verlag, Berlin-Heidelberg-New York 1983; 369–379
   Google Scholar
• Ciobanu N, Welte K, Kruger G, Venuta S, Gold J, Feldman S P, Wang C Y, Moore M AS, Safai B, Mertelsmann R. Defective T cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2. J Clin Immunol 1983; 3: 332–340
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Welte K, Mertelsmann R, Kernan N, Venuta S, Feldman S, Ciobanu N, Kruger G, Kirkpatrick D, Dupont B, O'Reilly R. Immunologic effects of interleukin 2 in primary immunodeficiency disease. J Immunol 1983; 130: 2644–2650
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoschimoto R, Jamuro J. Structure and expression of a cloned cDNA for human interleukin 2. Nature (London) 1983; 302: 305–310
   PubMed Web of Science ®Google Scholar
• Welte K, Mertelsmann R, Einzig A, Merluzzi V, Stabinsky Y, Boone T, Souza L. Recombinant interleukin 2 and human lymphocyte interleukin 2 are able to restore defective mitogen responses in patients with immunodeficiency states. Blood 1983; 62(Suppl 1)377, Abstract
   Google Scholar
• Gillis S, Ferm M, Ou W, Smith K A. T cell growth factor: Parameters of production and quantitative microassay for activity. J Immunol 1978; 120: 2027–2035
   PubMed Web of Science ®Google Scholar
• Smith K A, Favata M F, Oroszlan S. Production and characterization of monoclonal antibodies of human interleukin 2: Strategy and tactics. J Immunol 1983; 131: 1808
   PubMed Web of Science ®Google Scholar
• Leonard W J, Depper M, Uchiyama T, Smith K A, Waldmann T A, Greene W C. A monoclonal antibody that appears to recognize the receptor for human T cell growth factor; partial characterization of the receptor. Nature (London) 1982; 300: 267
   PubMed Web of Science ®Google Scholar
• Robb R J, Smith K A. Heterogeneity of human T cell growth factor(s) due to variable glycosylation. Molecular Immunol 1981; 18: 1087–1094
   PubMed Web of Science ®Google Scholar
• Robb R J, Kutny R M, Chowdhry V. Purification and partial sequence analysis of human T cell growth factor. Proc Natl Acad Sci 1983; 80: 5990–5994
   PubMed Web of Science ®Google Scholar
• Schneider U, Schwenk H U, Bunkamm G. Characterization of EBV-genome negative null and T cell lines derived from children with acute lymphoblastic and leukemic transformation of non-Hodgkin's lymphoma. Int J Cancer 1977; 19: 621–629
   PubMed Web of Science ®Google Scholar
• Devos R, Plaetinck G, Cheroutre H, Simons G, Degrave W, Tavernier J, Remaut E, Fiers W. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res 1983; 11: 4307
   PubMed Web of Science ®Google Scholar
• Tarella C, Ruscetti F W, Poiesz B J, Woods A, Gallo R C. Factors that affect human hemopoiesis are produced by T cell growth factor dependent and independent cultured T cell leu-kemia-lymphoma cells. Blood 1982; 59: 1330–1336
   PubMed Web of Science ®Google Scholar
• Gillis S. Interleukin 2: Biology and biochemistry. J Clin Immunol 1983; 3: 29
   Google Scholar
• Robb R J, Munck R A, Smith K A. T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med 1981; 154: 1455–1474
   PubMed Web of Science ®Google Scholar
• Robb R J, Greene W C. Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen. J Exp Med 1983; 158: 1332
   PubMed Web of Science ®Google Scholar
• Feldman S P, Mertelsmann R, Venuta S, Andreeff M, Welte K, Moore M AS. Sodium azide enhancement of interleukin 2 production. Blood 1983; 61: 815–818
   PubMed Web of Science ®Google Scholar
• Lando Z, Sarin P, Megson M, Greene W C, Waldman T A, Gallo R C, Broder S. Association of human T cell leukemia/lymphoma virus with the Tac antigen marker for the human T cell growth factor receptor. Nature 1983; 305: 733–736
   PubMed Web of Science ®Google Scholar
• Johnson H M, Farrar W L. The role of a gamma interferon-like lymphokine on the activation of T cells for expression of interleukin 2 receptors. Cellular Immunol 1983; 75: 154–159
   PubMed Web of Science ®Google Scholar
• Kuribayashi K, Gillis S, Kern D E, Henney C S. Murine NK cell cultures: Effects of interleuin 2 and interferon on cell growth and cytotoxic reactivity. J Immunol 1981; 126: 2321–2327
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Broder S, Waldmann T A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393
   PubMed Web of Science ®Google Scholar
• Gullberg M, Ivarsa F, Coutinho A, Larsson E. Regulation of T cell growth factor production: Arrest of TCGF production after 18 hours in normal lectin-stimulated mouse spleen cell cultures. J Immunol 1981; 127: 407–411
   PubMed Web of Science ®Google Scholar
• Soderquist A M, Carpenter G. Developments in the mechanism of growth factor action: Activation of protein kinase by epidermal growth factor. Fed Proc 1983; 42: 2615
   PubMedGoogle Scholar
• Sekaly R P, Macdonald H R, Zaech P, Nabholz M. Cell cycle regulation of cloned cytolytic T cells by T cell growth factor: Analysis by flow microfluorometry. J Immunol 1982; 129: 1407
   PubMed Web of Science ®Google Scholar
• Reinherz E L, Meuer S, Fitzgerald K A, Hussey R E, Levine H, Schlossman S F. Antigen recognition by human T lymphocytes is linked to surface expression of the T3 molecular complex. Cell 1982; 30: 735
   PubMed Web of Science ®Google Scholar
• Van Wauwe J P, Demey J R, Goossens J G, Okt. A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708
   PubMed Web of Science ®Google Scholar
• Chang T W, Kung P C, Gingras S P, Goldstein G. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells. Proc Natl Acad Sci USA 1981; 78: 1805
   PubMed Web of Science ®Google Scholar
• Welte K, Platzer E, Wang C Y, Rinnooy Kan EA, Moore M AS, Mertelsmann R. OKT8 antibody inhibits OKT3-in-duced IL2 production and proliferation in OKT8 cells. J Immunol 1983; 131: 2356–2361
   PubMed Web of Science ®Google Scholar
• Von Wussow P C, Platsoucas C D, Wiranowska-Stewart M, Stewart W E. Human gamma interferon production by leukocytes induced with monoclonal antibodies recognizing T cells. J Immunol 1981; 127: 1197
   PubMed Web of Science ®Google Scholar
• Platsoukas C D, Good R A. Inhibition of specific cell mediated cytotoxicity by monoclonal antibodies to human T cell antigens. Proc Natl Acad Sci USA 1981; 78: 4500
   PubMed Web of Science ®Google Scholar
• Landegren U, Ramstedt U, Axberg I, Ullberg M, Jondal M, Wigsell H. Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu 2a antibodies. J Exp Med 1982; 155: 1579–1584
   PubMed Web of Science ®Google Scholar
• Meuer S C, Hussey R E, Hodgdon J C, Hercend T, Schlossman S F, Reinherz E L. Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 1982; 218: 471
   PubMed Web of Science ®Google Scholar
• Reinherz E L, Hussey R E, Schlossman S F. A monoclonal antibody blocking human T cell function. Eur J Immunol 1980; 10: 758
   PubMed Web of Science ®Google Scholar
• Wakasugi H, Harel A, Dokhelar M C, Fradelizi D, Tursz T. Leukemia cell lines can replace monocytes for mitogen induced T lymphocyte responses: This accessory function is dependent upon their differentiation stage. Proc Natl Acad Sci USA 1983; 80: 6028
   PubMed Web of Science ®Google Scholar
• Van Wauwe J P, Goossens J G. The mitogenic activity of OKT3 and anti-Leu 4 monoclonal antibodies: A comparative study. Cell Immunol 1983; 77: 23
   PubMed Web of Science ®Google Scholar
• Steplewski Z, Lubeck M D, Koprowski H. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 865
   PubMed Web of Science ®Google Scholar
• Reinherz E L, Kung P C, Goldstein G, Schlossman S F. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci USA 1979; 76: 4961
   PubMedGoogle Scholar
• Reinherz E L, Kung P C, Goldstein G, Schlossman S F. Further characterization of the human inducer T cell subset defined by monoclonal antibody. J Immunol 1979; 123: 2894
   PubMed Web of Science ®Google Scholar
• Reinherz E L, Kung P C, Breard J M, Goldstein G, Scholssman S F. T cell requirements for generation of helper factor(s) in man: Analysis of the subsets involved. J Immunol 1980; 124: 1883
   PubMed Web of Science ®Google Scholar
• Thomas Y, Sosman J, Irigoyen O, Friedman S M, Kung P C, Goldstein G. Functional analysis of human T cell subsets defined by monoclonal antibodies. I. Collaborative T-T interactions in the immunoregulation of B cell differentiation. J Immunol 1980; 125: 2402
   PubMed Web of Science ®Google Scholar
• Meuer S C, Hussey R E, Penta A C, Fitzgerald K A, Stadler B M, Schlossman S F. Cellular origin of interleukin 2 (IL2) in man: Evidence for stimulus restricted IL2 production by T4+ and T8+ T lymphocytes. J Immunol 1982; 129: 1076
   PubMed Web of Science ®Google Scholar
• Luger T A, Smolen J S, Chused T M, Steinberg A D, Op-Penheim J J. Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest 1982; 70: 470
   PubMed Web of Science ®Google Scholar
• Grimm E A, Mazumder A, Zhang H Z, Rosenberg S A. Lym-phokine activated killer cell phenomenon lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823
   PubMed Web of Science ®Google Scholar
• Depper J M, Leonard W J, Robb R J, Waldmann T A, Green W C. Blockade of the interleukin 2 receptor by anti-Tac antibody: Inhibition of human lymphocyte activation. J Immunol 1983; 131: 690
   PubMed Web of Science ®Google Scholar
• Pearlstein K T, Palladino M A, Welte K, Vilcek J. Purified human interleukin 2 enhanced induction of immune interferon. Cellular Immunol 1983; 80: 1–9
   PubMed Web of Science ®Google Scholar
• Kasahara T, Hooks J J, Dougherty S F, Oppenheim J J. Interleukin 2 mediated immune interferon (IFN-gamma) production by human T cells and T cell subsets. J Immunol 1983; 130: 1784
   PubMed Web of Science ®Google Scholar
• Czech M P, Oppenheimer C L, Massague J. Inter-relationships among receptor structures for insulin and peptide growth factors. Fed Proc 1983; 42: 2598
   PubMedGoogle Scholar
• Palacios R, Moller G. Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature (London) 1981; 290: 792–794
   PubMed Web of Science ®Google Scholar
• Hess A D, Tutschka P J, Santos G W. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982; 128: 355
   PubMed Web of Science ®Google Scholar
• Hess A D, Tutschka P J, Pu Z, Santos G W. Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness of these growth factors in CsA-treated primary MLR cultures. J Immunol 1982; 128: 360
   PubMed Web of Science ®Google Scholar
• Ryffel B, Gotz U, Heuberger B. Cyclosporin receptors on human lymphocytes. J Immunol 1982; 129: 1978
   PubMed Web of Science ®Google Scholar
• Bunjes D, Hardt C, Rollinghoff M, Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 1981; 11: 657
   PubMed Web of Science ®Google Scholar
• Wagner H. Cyclosporin A: Mechanism of action. Transplant Proc 1983; 15: 523
   Web of Science ®Google Scholar
• Reem G H, Cook L A, Vilcek J. Gamma Interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A. Science 1983; 221: 63
   PubMed Web of Science ®Google Scholar
• Larsson E L. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 1980; 124: 2828
   PubMed Web of Science ®Google Scholar
• Gillis S, Kozak R, Durante M, Weksler M E. Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest 1981; 67: 937–942
   PubMed Web of Science ®Google Scholar
• Siegal F P, Lopez C, Hammer G S, et al. Severe acquired immunodeficiency in male homosexuals manifested by chronic perianal ulcerative herpes simplex lesions. New Engl J Med 1981; 305: 1439–1444
   PubMed Web of Science ®Google Scholar
• Gottlieb M S, Schroff R, Schanker M M, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. New Engl J Med 1981; 305: 1425–1431
   PubMed Web of Science ®Google Scholar
• Koziner B, Denny T, Myskowski P L, Kris M, Safai B. New Engl J Med 1982; 306: 933–934, (Letter to the Editor)
   Google Scholar
• Lederman M M, Ratnoff O D, Scillian J J, Jones P K, Schacter B. Impaired cell mediated immunity in patients with classic hemophilia. Med Intell 1983; 308: 79
   Google Scholar
• Menitove J E, et al. T lymphocyte populations in patients with classic hemophilia treated with cryoprecipitate and lympholized concentrates. Med Intell 1983; 308: 83
   Google Scholar
• Luban L, Kelleher J F, Reaman G H. Altered distribution of T lymphocyte subpopulations in children and adolescents with hemophilia. Lancet 1983; 1: 503
   PubMed Web of Science ®Google Scholar
• Gill J C, Menitove J E, Wheeler D, et al. Generalized lymphadenopathy and T cell abnormalities in hemophilia A. J Pediat 1983; 102: 1–18
   PubMedGoogle Scholar
• Landay A, Poon M C, Abo T, Stagno S, Lurie A, Cooper M D. Immunologic studies in asymptomatic hemophilia patients. J Clin Invest 1983; 71: 1500
   PubMed Web of Science ®Google Scholar
• Bussel J B, Welte K, Ciobanu N, Hilgartner M W, Mer-Telsmann R, T cell abnormalities in patients with hemophilia: Improvement of proliferation to three mitogens upon addition of highly purified interleukin 2 and the relationship to associated conditions, unpublished
   Google Scholar
• Gupta S, Good R A. Markers of human lymphocyte sub-populations in primary immunodeficiency and lymphoproliferative disorders. Sem Hematol 1980; 17: 1–29
   PubMed Web of Science ®Google Scholar
• Webster A DB, Anderson G L. Identification and function of T cells in the peripheral blood of patients with hypogammablogulinemia. Clin Exp Immunol 1974; 8: 499–504
   Google Scholar
• WHO Immunodeficiency report of a WHO scientific group. Clin Immunol Immunopath 1979; 13: 296–359
   PubMedGoogle Scholar
• Cunningham-Rundles S, Cunningham-Rundles C, Madi, Siegal S P, Kosloff C, Good R A. Impaired proliferative response to B lymphocyte activators in common variable immunodeficiency. J Clin Immunol 1981; 1: 65–72
   PubMedGoogle Scholar
• Siegal G P, Good R A. Human lymphocyte differentiation markers and their application to immune deficiency and lymphoproliferative disease. Clin Haematol 1977; 6: 355–422
   PubMedGoogle Scholar
• Preud'homme J L, Giscelli C, Seligmann M. Immunoglobulins on the surface of lymphocytes in 50 patients with primary immunodeficiency disease. Clin Immunol Immunopathol 1973; 1: 241–256
   PubMedGoogle Scholar
• Waldmann T A, Blaese R M, Broder S, Krakauer R S. NIH Conference: Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. Ann Intern Med 1978; 88: 226–238
   PubMed Web of Science ®Google Scholar
• Schwartz S A, Choi Y S, Shou L. Modulatory effects on immunoglobulin synthesis and secretion by lymphocytes from immunodeficient patients. J Clin Invest 1976; 50: 1176–1187
   Google Scholar
• Siegal F P, Siegal M, Good R A. Suppression of plasma cell formation by leukocytes from hypogammaglobulinemia patients. J Clin Invest 1976; 58: 109–122
   PubMed Web of Science ®Google Scholar
• Siegal F P, Siegal M, Good R A. Role of helper, suppressor and B cell defects in the pathogenesis of the hypogammablogulinemias. New Engl J Med 1978; 29: 172–178
   Google Scholar
• De La Concha E G, Oldham G, Webster A BD, Asherson G L, Platts-Mills T AE. quantitative measurements of T and B cell function in “variable” primary hypogammablogulinemia: Evidence for a consistent B cell defect. Clin Exp Immunol 1977; 127: 208–215
   Google Scholar
• Kruger G, Welte K, Ciobanu N, Cunningham-Rundles C, Ralph P, Venuta S, Feldman S, Wang C Y, Moore M AS, Mertelsmann R. Interleukin 2 correction of defective in vitro T cell mitogenesis in patients with combined varied immunodeficiency. J Clin Immunol 1984; 4: 295
   PubMed Web of Science ®Google Scholar
• Saiki O, Ralph P. Three distinct stages of B cell defects in common varied immunodeficiency. Proc Natl Acad Sci USA 1982; 79: 6008–6012
   PubMed Web of Science ®Google Scholar
• Noel D R, Witherspoon R P, Storb R, Atkinson K, Doney K, Michelson E M, Ochs H D, Warren R P, Weiden P L, Thomas E D. Does graft-versus-host disease influence the tempo of immunological recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978; 51: 1087
   PubMed Web of Science ®Google Scholar
• deBruin H G, Astaldi A, Leupers T, van de Griend R J, Dooren L J, Schellekens P TA, Tanke H J, Roos M, Vossen J M. T lymphocyte characteristics in bone marrow-transplanted patients. II. Analysis with monoclonal antibodies. J Immunol 1981; 127: 244
   PubMed Web of Science ®Google Scholar
• Witherspoon R P, Lum L G, Storb R, Thomas E D. In vitro regulation of immunoglobulin synthesis after human marrow transplantation. II. Deficient T and non-T lymphocyte function within 3–4 months of allogeneic, syngeneic, or autologous marrow grafting for hematologic malignancy. Blood 1982; 59: 844
   PubMed Web of Science ®Google Scholar
• Friedrich W, O'Reily R J, Koziner B, Gebhard D F, Jr, Good R A, Evans R L. T lymphocyte reconstitution in recipients of bone marrow transplants with and without GvHD: Imbalances of T cell subpopulations having unique regulatory and cognitive functions. Blood 1982; 59: 696
   PubMed Web of Science ®Google Scholar
• Fox R, McMillan R, Spruce W, Tani P, Mason D. The Scripps Clinic Bone Marrow Transplantation Team: Analysis of T lymphocytes after bone marrow transplantation using monoclonal antibodies. Blood 1982; 60: 578
   PubMed Web of Science ®Google Scholar
• Donnenberg A D, Elfenbein G J, Santos G W. Cell-cell cooperation in lymphocyte colony formation: Studies in human allogeneic marrow transplantation. J Immunol 1982; 129: 1080
   PubMed Web of Science ®Google Scholar
• Schroff R W, Gale R P, Fahey J L. Regeneration of T cell subpopulations after bone marrow transplantation: cytomegalovirus infection and lymphoid subset imbalance. J Immunol 1982; 129: 1926
   PubMed Web of Science ®Google Scholar
• Mori T, Tsoi M S, Gillis S, Santos E, Thomas E D, Storb R. Cellular interactions in marrow-grafted patients. I. Impairment of cell mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2. J Immunol 1983; 130: 712
   PubMed Web of Science ®Google Scholar
• Welte K, Ciobanu N, Moore M AS, Gulati S, O'Reilly R J, Mertelsmann R. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 1984; 64: 380
   PubMed Web of Science ®Google Scholar
• Antonacci A C, Good R A, Gupta S. T-cell subpopulations following thermal injury. Surg Gynecol Obstet 1982; 155: 1–8
   PubMedGoogle Scholar
• Antonacci A, Calvano S E, Reaves L E, Welte K, Mertelsmann R, Shires G T. Restoration of autologous mixed lymphocyte responses in burn patients following in vitro addition of interleukin 2: Analysis of responder cell populations with monoclonal antibodies. Surg Forum 1983; 34: 108
   Google Scholar
• Antonacci A, Calvano S E, Reaves L E, Prajapati A, Bockman R, Welte K, Mertelsmann R, Gupta S, Good R A, Shires G T. Autologous and allogeneic mixed lymphocyte responses following thermal injury in man: The immunomodulatory effects of interleukin 1, interleukin 2 and a prostaglandin inhibitor, WY-18251. Clin Immunol Immunopath 1984; 30: 304–320
   PubMedGoogle Scholar
• Rosenstein M, Eberlein T, Kemeny M M, Shugarbaker P H, Rosenberg S A. In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor. J Immunol 1981; 127: 568–571
   Google Scholar
• Cheever M A, Greenberg P D, Fefer A. Gillis S: Augmentation of the antitumor therapeutic efficacy of long term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982; 155: 968–980
   PubMed Web of Science ®Google Scholar
• Gifford R RM, Ferguson R M, Goss B V. Cimetidine reduction of tumor formation in mice. Lancet 1981; 1: 638–640
   PubMed Web of Science ®Google Scholar
• Damle N K, Gupta S. Autologous mixed lymphocyte reaction in man. II. Histamine-induced suppression of the autologous mixed lymphocyte reaction by T cell subsets defined with monoclonal antibodies. J Clin Immunol 1981; 1: 241–249
   Web of Science ®Google Scholar
• Borgstrom S, von Eyben F E, Axelsson B, Sjogren H O. Human leukocyte interferon and cimetidine for metastatic melanoma. New Engl J Med 1982; 307: 1080–1081
   PubMed Web of Science ®Google Scholar
• Cheever M A, Greenberg P D, Fefer A. Therapy of leukemia by nonimmune syngeneic spleen cells. J Immunol 1980; 124: 2137
   PubMed Web of Science ®Google Scholar
• Cheever M A, Greenberg P D, Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol 1980; 125: 711
   PubMed Web of Science ®Google Scholar
• Lubet R A, Clarlson D E. Therapy of the murine plasmacytoma MOPC 104E: Role of the immune response. J Natl Cancer Inst 1978; 61: 897
   PubMed Web of Science ®Google Scholar
• Moore M AS, Williams D E. Contribution of host immunity to cyclophosphamide therapy of a chemically induced murine sarcoma. Int J Cancer 1973; 11: 358
   PubMed Web of Science ®Google Scholar
• Mertelsmann R, Welte K, Sternberg C, O'Reilly R, Moore M AS, Oettgen H F, Clarkson B D. In vivo effects of human lymphocyte interleukin 2 (IL2) in patients with acquired immunodeficiency syndrome (AIDS) and Iymphoproliferative diseases. Blood 1983; 62(Suppl 1)359, Abstract
   Google Scholar